Alessandro Di Federico

Mucinous lung adenocarcinoma (LUAD-Muc) is a WHO-recognized rare subtype of LUAD. Our study in @Annals_Oncology aimed to characterize clinicopathologic, genomic, immunophenotypic & transcriptional features differentiating these tumors form other LUADs 1/9 annalsofoncology.org/article/S0923-…

@DrMarkAwad and @pecci_federica1 share new findings that suggest survival benefits may persist even after stopping ICI treatment. 🔗 Learn more in ILCN: bit.ly/45Qw6qm

What about the rare stuff? @BRicciutiMD sheds light in what to do in patients with AGAs that could potentially respond to IO, such as MET, BRAF and KRAS. And it would not be Biagio without an opinion on STK11/KEAP1 co-mutations. #ASCO25

Our @VJOncology discussion on lung cancer highlights from #ASCO25 with @alessi_joao is also available on YouTube 👇 @IASLC @ASCO @OncoAlert @EGFRResisters @oncodaily youtube.com/watch?v=MPmobo…

Pleased to discuss some of the ASCO 2025 lung cancer highlights with my dear friend and colleague @alessi_joao in this @VJOncology podcast 👇

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer buff.ly/WnSosZu This multicenter cohort study evaluated the efficacy of neoadjuvant PD-1/PD-L1 blockade combined with platinum-based…

In a new @JAMAOnc study, @BRicciutiMD @DanaFarber found chemoimmunotherapy before surgery may offer a path forward for patients with advanced stage III non-small cell lung cancer. Read more: bit.ly/445t1li

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… @DrMarkAwad @BRicciutiMD

Such a privilege to listen to Dr. Crinò—my first mentor—reflecting on 20 years of progress in #LungCancer treatment, from targeted therapies to immunotherapies. A masterclass in science and dedication in #Ferrara 🇮🇹. @OncoAlert @DanaFarber @iascl

🎥 @DiFedericoMD of @DanaFarber highlights key biomarkers from FRONT-BRAF: PD-L1 ≥1%, smoking history & TP53 co-mutations predict better outcomes with immunotherapy in BRAF-mutated lung cancer. 📺 Watch ➡ ow.ly/9oZ250W4OOj @ASCO #ASCO25 #LungCancer #NSCLC #ImmunoOnc

Amazing work, Alessandro. This poster has the power to change our view on those patients. You rock!

With the best at #ASCO25 Last day and then Boston and/or Italy And our Brazilian transplant Dr. @MarceloCorassa Early stage session with a focus on target mutations

FRONT-BRAF: 1L immunotherapy +/- chemo vs. BRAF + MEK inhibitors in mNSCLC presented by my friend and colleague @DiFedericoMD a very kind-hearted, dedicated thoracic oncologist with a bright future ahead 🌟 🇮🇹 🇺🇸 #ASCO25 youtu.be/WgSUjS7xRJQ?si… via @YouTube

Α big lung cancer family comes together every year and @ASCO united by a common passion and vision and of course by our unique host @marinagarassino !! #ASCO25

Proud of Drs. #ValentinaSanto & #EleonoraGariazzo—talented, humble, & patient-centered—for presenting their work on biomarkers of response/resistance to #ICI in pts w/ #SqNSCLC (42) & w/o history of smoking (43) at #ASCO25. #IMG true force for progress. @thenasheffect @ASCO

Alessandro @DiFedericoMD with an amazing piece of work. And there are few people that can use a beige suit with finesse! Congrats for the work!

@DiFedericoMD presenting our collaborative study on 1st line BRAF/MEKi vs. #ICI for mNSCLC at #ASCO2025. ⬆️ OS with #ICI particularly in pts w/ PDL1 >1%, h/ tobacco use & TP53m. @ASCO @MarceloCorassa @mvnegrao @DanaFarber @MDAndersonNews @MSKCancerCenter

The KROCUS trial has shown promising results for the combination of fulzerasib (GFH925, a KRAS G12C inhibitor) and cetuximab in patients with KRAS G12C+ NSCLC. Tomorrow in Barcelona, we’ll explore next steps to advance treatment and improve outcomes for this patient group.